Clinical trial · Interventional
A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer
Factors That Regulate Components of a Nutritional Supplement to Support Skeletal Muscle in Cancer Patients
NCT02745197CI-TRIAL-00080760withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): change in concept
Summary
Brief summary (as posted)
This study evaluates a nutritional supplement in the treatment of pancreatic cancer in adults. Half of the participants will receive the nutritional supplement, while the other half will receive a placebo.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nutritional Supplement | Dietary Supplement | — | UNRESOLVED |
| Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Nutritional Supplement
- description
- 2 nutritional supplement capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
- interventionNames
- Dietary Supplement: Nutritional Supplement
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- 2 placebo capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
- interventionNames
- Dietary Supplement: Placebo
Primary outcomes (1)
- measure
- Muscle fatty acid content
- timeFrame
- At time of tumor removal surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a newly diagnosed pancreatic tumor thought to be pancreatic cancer scheduled for resection of the tumor. * Patients with a newly diagnosed pancreatic tumor thought to be pancreatic cancer, subsequently found to have biliary or ampullary cancer upon full pathological review, scheduled for resection of the tumor. * Patients with a CT image, which includes scans of the 3rd lumbar region, taken within 45 days before tumor resection surgery. * Ability to maintain oral intake. * Ability to give written, informed consent. Exclusion Criteria: * Patients found to have a diagnosis other than pancreatic, biliary, or ampullary cancer upon full pathological review. * Patients with a benign tumor. * Patients taking drugs that modify muscle metabolism. * Patients with uncontrolled jaundice. * A compliance rate of \<80%, excluding compliance during recovery from tumor resection surgery while in the hospital. * Patients currently taking the nutritional supplement being investigated in this study. * Patients in the placebo group who have plasma levels of the nutritional supplement components within the range of the nutritional supplement group at study time points when plasma levels of the nutritional supplement components are significantly higher in the nutritional supplement group versus the placebo group. * Inadequate specimens. * Known allergy to gelatin or glycerin.
References
Publications (0)
Data not yet available
No reference posted for this study.